Last reviewed · How we verify

NCT06864039: CHQoL

Quality of Life and Long-term Outcome of Adequately Treated Congenital Hypothyroidism

ENROLLING BY INVITATION NA Last updated 7 March 2025
What this trial tests

NA trial testing SF36 test in Congenital Hypothyroidism in 150 participants. Enrolling by invitation.

Timeline
6 September 2024
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorFederico II University
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment150
Start date6 September 2024
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Federico II University

Who can join

Adults 16 to 21, any sex, with Congenital Hypothyroidism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this observational study is the evaluation of the quality of life and long-term outccome of young-adult patients with congenital hypothyroidism diagnosed by neonatal screening receiving replacement treatment with levothyroxine. The secondary objective is to relate the results to the form of hypothyroidism, the initial dose of L-T4, treatment adherence and genetics

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Congenital Hypothyroidism

Currently open trials in the same condition.

Other Federico II University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06864039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing